Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Anti-CD3/undisclosed target bispecific T-cell engager |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), MUC17 inhibitors(mucin 17, cell surface associated inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastroesophageal junction adenocarcinoma | Discovery | China | 30 Nov 2023 |